OM1 launches curated real-world dataset for Parkinson’s disease to further neuroscience real-world evidence

OM1 expands its research-grade Mental Health and Neuroscience Real-World Data Network with a Parkinson’s disease curated dataset.

Leading real-world data (RWD) and technology company OM1 has announced it is launching a research-grade dataset of curated RWD for Parkinson’s disease (PD), expanding its Mental Health and Neuroscience RWD Network. The research resource comprises a premium dataset from over 7000 people with PD followed prospectively by neurologists, plus data from 700,000 individuals with PD in the OM1 Real-World Data Cloud.

Nearly 1 million people in the US are diagnosed as living with PD and no interventions that meaningfully reduce the progression of the disease have yet been developed. It is hoped the RWE insights that can be gleaned from this deep clinical data, into the journeys of people with PD, will ultimately drive improved care and outcomes.

“Understanding treatments and disease progression in patients suffering from this devastating illness with real-world data is critical for driving clinical advancements,” said Carl Marci, MD, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. “Among our goals is to break down barriers that impede access to deep clinical insights that otherwise would go unseen and unused to help develop personalized and targeted treatments for patients with Parkinson’s disease.”

The core of OM1’s new offering is the PD premium dataset, which constitutes data from more than 7000 patients prospectively followed by neurologists in hundreds of clinics across all 50 American states. OM1 uses its unique artificial intelligence and machine learning modeling capabilities to extract and enrich relevant longitudinal data from clinician’s notes. Data points feature key symptoms, disease severity, treatments, longitudinal outcomes, and clinical response.

In addition to the premium dataset, the OM1 Real-World Data Cloud makes available data from 700,000 people with PD, suitable for modeling health economics outcomes, patient recruitment for clinical trials, prescriber trends, and other research needs. The RWD sources include electronic medical records, medical and pharmacy claims, mortality data and social determinants of health.

This latest announcement of growth of OM1’s Mental Health and Neuroscience RWD Network follows their March launch of datasets for bipolar disorder and schizophrenia. They have reported that the next addition planned is a resource for Alzheimer’s disease.